Baird raised its price target on Incyte following positive Phase 2b results of Baricitinib which confirmed earlier data. Baird is optimistic about its Phase 3 program. Shares are Outperform rated.
Finance expert Suze Orman has voiced concerns about the impact of climate change on property insurance costs, asserting it could threaten the American dream of homeownership. Orman, 72, faced a $28,000 annual insurance quote for her Florida oceanside condo, leading her to forego coverage entirely. She highlights a troubling trend where soaring insurance costs driven by frequent and severe weather events may deter Americans from buying homes. Don't Miss: For many first-time buyers, a house is abo
Here's what could happen next to Meta Platforms' stock.
After Congress approved billions of extra funding for tax compliance, the Internal Revenue Service pledged it would get tougher on rich taxpayers and corporations while avoiding extra scrutiny of middle-class households.
After a dismal quarter for Tesla, CEO Elon Musk tried to reassure investors the company’s real value was its effort to perfect self-driving cars.
Six teams managing nearly $15 billion in total assets quit JPMorgan Chase’s brokerage unit to join competitors last Friday. Here’s what may have triggered their departures.
When it comes to reliable passive income, these three dividend-paying companies are best in breed.
The US dollar continues to pressure the 155 level showing signs of perhaps trying to break out given enough time.
Billionaire investors are ditching the "infrastructure backbone" of the artificial intelligence (AI) revolution in favor of two industry-leading, irreplaceable AI stocks.
The premier name among retail REITs, along with a 14%-yielding REIT that's returned $25 billion to its shareholders since going public, make for sensational buys right now.
Intel is underperforming the broader semiconductor index.
